News

Researchers have discovered a novel biomolecule, glycoRNA, that could play a significant role in the biology of all living things.

A new technology from UZH researchers enables the body to produce therapeutic agents on demand at exactly the point where they are needed. The innovation could reduce the side effects of cancer therapy and help better deliver COVID-19 treatments to the lungs.

Calcium-binding tyrosine phosphorylation-regulated protein (CABYR) is considered a cancer testis protein. Researchers evaluate the CABYR isoforms: a/b and c mRNA expression in colorectal cancer to determine if these proteins hold promise as vaccine targets.

Chemical engineering researchers have created several different types of nanoparticles and analyzed them for the ability to deliver and protect siRNA-based therapeutics from the body's immune system.

Researchers are using mice to show how a combination of peptides and oncolytic viruses, used as an adjuvant, can provide effective immunization against cancer.

A study has found that delaying the second dose of covid-19 vaccines, at least for people aged under 65, could result in up to 20% lower mortality, but only under certain conditions.

A dengue virus vaccine candidate has shown promising results in animal models, producing a protective immune response in dengue-infected mice.

According to a new preclinical study, cytokine-activated natural killer (NK) cells combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells.

Researchers have developed a peptide that, in mice, allowed the main component of Cannabis sativa to fight chronic pain without impacting memory and other cognitive functions.

Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses that continue to threaten global health.